Idera Pharmaceuticals to Present at Upcoming Conferences
January 11 2021 - 6:02AM
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it
will provide a company outlook for 2021 at upcoming conferences.
“2021 represents a pivotal inflection point for Idera, one in
which we anticipate that data soon to be available from our
ILLUMINATE program will show that tilsotolimod, the most advanced
TLR9 agonist therapy in development, can offer meaningful
alternatives to patients suffering from advanced anti-PD-1
refractory melanoma and, potentially, colorectal cancer,” stated
Vincent Milano, Idera’s Chief Executive Officer. “We’re looking
forward to sharing topline response data from ILLUMINATE-301 late
in this quarter and a data update from ILLUMINATE-206 in the third
quarter of the year.”
Continued Mr. Milano, “Our entire team is driven by our goal of
making a difference for patients and is unified in its persistence
to help ensure the quality of our clinical results, NDA and
commercial readiness, and a strong financial outlook that includes
existing cash that is expected to take us into the first quarter of
2022. We have confidence that this is the year Idera will deliver
on its long history of innovative science and begin to turn that
history into a business reality.”
The Company plans to share further corporate and ILLUMINATE
program updates at the following conferences in January:
- 39th Annual J.P.
Morgan Healthcare Conference, January 11-14,
2021Presentation on January 13, 2021, 3:40 pm EST
- H.C. Wainwright BioConnect 2021 Conference, January
11-14, 2021Pre-recorded conversation available January 11,
2021, 6:00 am EST
Live and archived webcasts of the investor conference
presentations will be available in the Investor Relations section
of the Idera website.
About Idera PharmaceuticalsHarnessing the
approach of the earliest researchers in immunotherapy and the
company’s vast experience in developing proprietary immunology
platforms, Idera’s development program is focused on priming the
immune system to play a more powerful role in fighting cancer,
ultimately increasing the number of people who can benefit from
immunotherapy. Idera also continues to focus on the acquisition,
development, and ultimate commercialization of drug candidates for
both oncology and rare disease indications characterized by small,
well-defined patient populations with serious unmet needs. To learn
more about Idera, visit www.iderapharma.com.
Forward Looking Statements This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. All statements,
other than statements of historical fact, included or incorporated
in this press release, including statements regarding the Company's
strategy, future operations, collaborations, intellectual property,
cash resources, financial position, future revenues, projected
costs, prospects, clinical trials, plans, and objectives of
management, are forward-looking statements. The words "believes,"
"anticipates," "estimates," "plans," "expects," "intends," "may,"
"could," "should," "potential," "likely," "projects," "continue,"
"will," and "would" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Idera
cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking
statements and you should not place undue reliance on the Company's
forward-looking statements. There are a number of important factors
that could cause Idera's actual results to differ materially from
those indicated or implied by its forward-looking statements.
Factors that may cause such a difference include: whether the
Company’s cash resources will be sufficient to fund the Company’s
continuing operations and the further development of the Company’s
programs for the period anticipated; whether interim results from a
clinical trial will be predictive of the final results of the
trial; whether results obtained in preclinical studies and clinical
trials will be indicative of the results that will be generated in
future clinical trials, including in clinical trials in different
disease indications; whether products based on Idera's technology
will advance into or through the clinical trial process when
anticipated or at all or warrant submission for regulatory
approval; whether such products will receive approval from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies; whether, if the Company's products receive approval, they
will be successfully distributed and marketed; whether the
Company's collaborations will be successful; and such other
important factors as are set forth under the caption "Risk factors"
in the Company’s Annual Report filed on Form 10-K for the period
ended December 31, 2019 and the Company’s Quarterly Report filed on
Form 10-Q for the period ended September 30, 2020. Although Idera
may elect to do so at some point in the future, the Company does
not assume any obligation to update any forward-looking statements
and it disclaims any intention or obligation to update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
Idera
Pharmaceuticals Contacts: |
|
|
|
|
|
Jill Conwell |
|
John J. Kirby |
|
Investor Relations & |
|
Chief Financial Officer |
|
Corporate Communications |
|
Phone (484) 348-1627 |
|
Phone (484) 348-1675 |
|
JKirby@IderaPharma.com |
|
JConwell@IderaPharma.com |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Sep 2023 to Sep 2024